Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination

Wright, Jason D.; Govindappagari, Shravya; Pawar, Neha; Cleary, Kirsten; Burke, William M.; Devine, Philip E.; Lu, Yu-Shiang; Tsai, Wei‐Yann; Lewin, Sharyn N.; Herzog, Thomas J.

doi:10.1097/aog.0b013e31826afb56

Cited by 26 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Completion may also be increased by incorporating HPV vaccination into postpartum visits, or into inpatient postpartum care, which Wright has shown to be feasible and acceptable to patients. 18 Females who become pregnant during the vaccination time frame are ineligible to complete the series during pregnancy at our institution, consistent with the American College of Obstetricians and Gynecologists' Committee Opinion. 11 Our finding of series "noncompletion" may therefore be series delay as a result of the pregnancy itself, at least among those with shorter follow-up times.…”

Section: Discussionmentioning

confidence: 68%

Factors Associated With Human Papillomavirus Vaccination Completion on a Catch-Up Schedule

Perry

Rankin

et al. 2014

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

Factors Associated With Human Papillomavirus Vaccination Completion on a Catch-Up Schedule

Perry

Rankin

et al. 2014

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…Provider recommendation for HPV vaccination is associated with increased vaccination 7,12 and prior research suggests that women find it acceptable to be offered and receive the HPV vaccine postpartum. 15,16 For any pregnant woman who has not received the vaccine before pregnancy, administration postpartum should be recommended and offered.…”

Section: Discussionmentioning

confidence: 99%

“…For women who have not previously received the HPV vaccine, the postpartum period may present an opportunity to vaccinate. Two studies have shown that women find it acceptable to be offered the HPV vaccine postpartum 15,16 and the majority of those who are interested (95%) initiate the vaccine. 16 The extent to which eligible women are initiating HPV vaccination postpartum is unknown.…”

mentioning

confidence: 99%

“…Two studies have shown that women find it acceptable to be offered the HPV vaccine postpartum 15,16 and the majority of those who are interested (95%) initiate the vaccine. 16 The extent to which eligible women are initiating HPV vaccination postpartum is unknown. Our objective is to estimate the proportion of vaccine-eligible women who initiate the HPV vaccine in the first year postpartum among a cohort of commercially insured women to evaluate potential missed opportunities for vaccination among women interacting with the healthcare system.…”

mentioning

confidence: 99%

“…2 In the United States, the rates of HPV vaccine initiation and completion are low. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of adolescents age 11-12 with a catch up period for females during the ages of [13][14][15][16][17][18][19][20][21][22][23][24][25][26]. 3 Despite recommendations, in a 2013 nationwide survey of 2077 women aged 19-26 years of age, only 37% reported previously receiving at least one HPV vaccine.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006–2012

Kilfoyle

Rahangdale

Dusetzina

2016

Journal of Women's Health

View full text Add to dashboard Cite

Background: Young adult women find it acceptable to be offered the human papillomavirus (HPV) vaccine postpartum. Little is known about the practice of administering the HPV vaccine during the postpartum period. Materials and Methods: The Truven Health Analytics MarketScan Commercial Claims and Encounters database was used to develop a cohort of privately insured 18 to 26-year-old women with uncomplicated live-born pregnancies. Eligibility required no previous doses of HPV vaccine before delivery and continuous insurance enrollment from June 2006 through 1 year postpartum. Descriptive statistics were performed. Results: A total of 51,913 women meet age and enrollment criteria, with 3912 (7.5%) having received any doses of vaccine before their delivery, leaving 48,001 women in this cohort. In the year postpartum, 861 women (1.8%) received any HPV vaccine. Of the women initiating the vaccine, only 337 (39%) completed the threevaccine series. Women who received the vaccine, compared with women who did not, were younger (21 vs. 23 years old), more often the dependent to the insurance beneficiary (56% vs. 30%), and were more likely to have had an abnormal pap smear in the year prior (19.6% vs. 9.1%) or postdelivery (16.4% vs. 4.9). More women completed the HPV vaccine series when initiated within 2 months postpartum compared with women initiating the vaccine series >2 months postpartum (44% vs. 38%). Conclusions: Postpartum women are eligible for the HPV vaccine, yet very few are receiving it. The postpartum period is a missed opportunity for administration of this cancer-preventing vaccine.

show abstract

Immunogenicity of 2-Dose HPV Vaccine Series for Postpartum Women

Moss,

Wang,

Sao

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportancePostpartum human papillomavirus (HPV) vaccination is a promising strategy to increase HPV vaccination uptake in the US, particularly for reaching vaccine-naive women and those who lack health insurance beyond the pregnancy period. However, completion of the 3-dose vaccine regimen is challenging.ObjectiveTo evaluate the immunogenicity of a 2-dose postpartum HPV vaccination regimen (0 and 6 months) and assess whether it is noninferior to a 3-dose postpartum HPV vaccination regimen (0, 1-2, and 6 months) administered to historical controls.Design, Setting, and ParticipantsA noninferiority, open-label, nonrandomized immunogenicity trial was conducted from August 4, 2020, to June 23, 2022, of postpartum patients aged 15 to 45 years who delivered at 2 hospitals in Baltimore, Maryland. Historical controls were adolescents and young women aged 16 to 26 years.InterventionTwo doses of the nonavalent HPV vaccine administered 6 months apart.Main Outcomes and MeasuresThe primary outcome was noninferiority (90% CI, lower bound &gt;0.67) of the geometric mean titer (GMT) ratio for HPV-16 among postpartum women compared with historical controls. Secondary outcomes were noninferiority of GMT ratios for the other 8 HPV types and percentage seroconversion for each HPV type. As a noninferiority trial, the primary analysis used the per-protocol analysis.ResultsOf 225 enrolled participants, the mean (SD) age at baseline was 29.9 (6.8) years, and 171 (76.0%) were HPV-16 seronegative at baseline. Of these 171 participants, 129 (75.4%) received a second vaccine dose and completed the subsequent 4-week serologic measurements. Relative to historical controls, the HPV-16 GMT ratio was 2.29 (90% CI, 2.03-2.58). At month 7, HPV-16 GMT was higher after the 2-dose regimen (7213.1 mMU/mL [90% CI, 6245.0-8331.4 mMU/mL]) than among historic controls after the 3-dose regimen (3154.0 mMU/mL [90% CI, 2860.2-3478.0 mMU/mL]). Similarly, the lower bound of the 90% CI of the GMT ratio was above 1 for the 8 HPV types 6, 11, 18, 31, 33, 45, 52, and 58. A total of 118 of 134 women (88.1%) seroconverted for HPV-16 after the first dose; 4 weeks after the second dose, the seroconversion rate was 99% or greater for all HPV types.Conclusions and RelevanceThis study suggests that immunogenicity of a 2-dose HPV vaccination regimen given 6 months apart among postpartum women was noninferior to a 3-dose regimen among young historical controls. Most women seroconverted after the first dose of the 2-dose regimen. These results demonstrate that postpartum vaccination using a reduced schedule may be a promising strategy to increase HPV vaccine series completion.Trial RegistrationClinicalTrials.gov Identifier: NCT04274153

show abstract

Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination

Abstract: II.

Cited by 26 publications

References 28 publications

Factors Associated With Human Papillomavirus Vaccination Completion on a Catch-Up Schedule

Factors Associated With Human Papillomavirus Vaccination Completion on a Catch-Up Schedule

Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006–2012

Immunogenicity of 2-Dose HPV Vaccine Series for Postpartum Women

Contact Info

Product

Resources

About